Related Experiment Video
Updated: Jun 2, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
Akira Fukutomi1, Kiyohiko Hatake, Kaoru Matsui
1Shizuoka Cancer Center, Shizuoka, Japan.
Objective:
The objective was to determine the maximum tolerated dose and the dose-limiting toxicity of panobinostat (LBH589) when administered as a single agent to adult patients with advanced solid tumors or cutaneous T-cell lymphoma whose disease had progressed despite standard therapy or for whom no standard therapy existed.
Methods:
Panobinostat was administered orally once daily on Monday, Wednesday, and Friday of each week. A total of 13 patients were treated with one of three initial doses: 10 mg (n = 3), 15 mg (n = 4), or 20 mg (n = 6).
Results:
No dose-limiting toxicity was observed in 12 evaluable patients. The most frequently reported adverse events, regardless of whether they were related to the study drug, were diarrhea and nausea in 10 patients (76.9%). Thrombocytopenia was reported in 12 of 13 patients (92.3%). Five of 11 patients (45.4%) had stable disease.
Conclusion:
Panobinostat administered orally once daily on Monday, Wednesday, and Friday of each week was well tolerated at doses up to 20 mg in Japanese patients. Dose escalation did not proceed after exploration of the 20 mg dose due to emerging global clinical data at that time.
Related Concept Videos
Clinical Trials: Overview
Bioavailability Study Design: Healthy Subjects Versus Patients
Treatment Resistent Cancers
Treatment Resistant Cancers
Bioavailability Study Design: Single Versus Multiple Dose Studies
Clinical Trials
There are four phases in a clinical trial. A phase one...
